Professor of Medicine
Nancy University Hospital
I am pleased to welcome you to this Takeda-organized educational symposium titled “Management of Crohn’s Disease: Current Concepts, Future Directions.”
Improved understanding of the pathophysiology of Crohn’s disease (CD) has progressively resulted in more effective medical treatments, from 5-aminosalicylic acid and steroids to immunomodulators and biologic therapies. James O. Lindsay will describe how advances in drug development—especially the advent of systemic anti-tumor necrosis factor (TNF) agents and gut-selective anti-integrin biologic therapy—have made it possible for patients to achieve more aggressive treatment goals of mucosal healing beyond the control of clinical symptoms, which may ultimately impact the natural history of CD. Dr Lindsay will also discuss the importance of a durable response and good tolerability with long-term treatment to achieving therapeutic goals in CD.
Despite the availability of new medical therapies, clinicians continue to face challenges in optimizing the management of CD. Iris Dotan will review optimal approaches to helping patients achieve their therapeutic goals, including determining the appropriate first-line biologic and treating patients who don’t respond or lose their response to anti-TNF drugs.
I am confident that this symposium will be an excellent forum for discussing the current and future outlook for the management of CD, and provide insights into how we can better help our patients cope with this challenging disease. On behalf of Dr Lindsay and Prof Dr Dotan, thank you for spending this early morning with us.
Laurent Peyrin-Biroulet, MD, PhD